Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults With Type 2 Diabetes: From Injections to Hybrid Closed-Loop Therapy
| Autor: | Georgia M. Davis, Anne L. Peters, Bruce W. Bode, Anders L. Carlson, Bonnie Dumais, Todd E. Vienneau, Lauren M. Huyett, Trang T. Ly |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Diabetes Care. 46:742-750 |
| ISSN: | 1935-5548 0149-5992 |
| DOI: | 10.2337/dc22-1915 |
| Popis: | OBJECTIVEAutomated insulin delivery (AID) has rarely been studied in adults with type 2 diabetes. We tested the feasibility of using AID for type 2 diabetes with the Omnipod 5 System in a multicenter outpatient trial.RESEARCH DESIGN AND METHODSParticipants previously were using either basal-only or basal-bolus insulin injections, with or without the use of a continuous glucose monitor (CGM), and had a baseline HbA1c ≥8% (≥64 mmol/mol). Participants completed 2 weeks of CGM sensor data collection (blinded for those not previously using CGM) with their standard therapy (ST), then transitioned to 8 weeks of AID. Participants who previously used basal-only injections used the AID system in manual mode for 2 weeks before starting AID. Antihyperglycemic agents were continued at clinician discretion. Primary safety outcomes were percentage of time with sensor glucose ≥250 mg/dL and RESULTSParticipants (N = 24) had a mean (± SD) age of 61 ± 8 years, baseline HbA1c of 9.4% ± 0.9% (79 ± 10 mmol/mol), and diabetes duration of 19 ± 9 years. Percentage of time with sensor glucose ≥250 mg/dL decreased with AID by 16.9% ± 16.2% (P < 0.0001), whereas percentage of time at CONCLUSIONSFindings from this feasibility trial of AID in adults with type 2 diabetes with suboptimal glycemic outcomes justify further evaluation of this technology in this population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|